At 5 pm on Monday, Bharat Biotech’s founder and chairman Dr Krishna Ella named for a virtual press conference in an apparent try to allay issues about the manner in which the emergency use authorisation was granted to the business.
Calling Bharat Biotech as a business that understands vaccines getting developed 16 vaccines and spread across 123 nations, he responded to a wide variety of inquiries from the media. Of these, a single was to seek his response to the tweet by Congress MP Shashi Tharoor questioning the manner in which the approval was granted with an apparent “unseemly haste.” Arguing that it was incorrect to say the business got a premature approval, he stated, “we are eligible and it is not a premature approval.” Quoting the CDSCO (Central Drugs Standard Control Organisation) recommendations and the gazette notification of 2019, he stated, “I am eligible after phase II based on five parameters.” The 2019 guidelines are for emergency conditions wherein authorisations could be provided to molecules on the basis of phase II information, he stated.
But then, to TheSpuzz Online query on the whether or not it was correct to feel that the approval was granted primarily based on phase II information alone, he stated, “the approval is not based on phase II data alone . It is based on our extremely good and proven technology platform. Second, it is based on extremely good efficacy data on animals – non human primates (monkeys) and hamsters, third it is based on good data from phase I then on good immunogenicity data (the amount of antibodies the vaccine can produce within the body) from phase II trials. And then, apart from these, based on extremely good neutralization (ability of the antibodies produced by the vaccine in the body to contain the virus) and T-cell response (also the key players in the immune response to a viral infection) in both human and animals. All these parameters mattered and it was based on all these and not just on the phase 2 clinical trials data, he said.
To other question on the amount of stock of vaccines already made and ready, he said, the company has a stockpile of 20 million doses and has plans to ramp up production to 700 million doses from four plants so supply should not be a problem. On whether the government had placed an order for the vaccine doses and if so, how many, he just confined himself to saying “the government is talking to us.”
He also denied as incorrect any assumption that the vaccine was getting viewed as as a back up vaccine. To him, this was a single more vaccine that was provided an emergency use authorisation and that there was no such factor as a back up vaccine.
On the essential query of what percentage protection the Bharat Biotech vaccine delivers and the plans for this in the phase III research (Pfizer for instance, says its vaccine delivers 95 per cent protection to these vaccinated) and when the phase 3 trials will be concluded, Dr Ella stated, “in the next two to three days, the first dose injections to the volunteers will be completed.” However, the second dosing of the vaccine had also began, he stated. “To almost 6,000 people the second dose has also been administered and this process will be completed in the first week of February. After this, the efficacy (or the protection) of the vaccine will be monitored. As of now, we do not know the efficacy percentage,” he stated. However, as per norms, he pointed out, regulators demand protection of not much less than 50 per cent (that is 50 per cent of the individuals not receiving infected when exposed to the virus immediately after vaccination).” But then, was fast to add: “Please do not quote that I am talking of 50 per cent efficacy but we are confident of much higher levels.”
1 Comment
I’m impressed, I need to say. Really rarely do I encounter a blog that’s both educative and entertaining, and let me tell you, you have got hit the nail on the head. Your thought is excellent; the difficulty is one thing that not enough persons are speaking intelligently about. Im very pleased that I stumbled across this in my seek for something relating to this.